News & Events

News


Tuesday February 04, 2020

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $238 Million with Approximately 42,100 TRx INGREZZA® (valbenazine) Full-Year 2019 Net Product Sales of $753 Million with Approximately 132,700 TRx SAN DIEGO , Feb. 4, 2020 /PRNewswire/ --  Neurocrine Biosciences, Inc.


Monday February 03, 2020

Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors

SAN DIEGO , Feb. 3, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Shalini Sharp to its Board of Directors. Ms. Sharp is the Chief Financial Officer and Executive Vice President of Ultragenyx, a clinical-stage biopharmaceutical company focused on


Monday January 20, 2020

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 4 SAN DIEGO , Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb. 4, 2020 .


Sunday January 12, 2020

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

- INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million with Approximately 42,100 TRx - INGREZZA® (valbenazine) Preliminary Full-Year 2019 Net Product Sales of Approximately $753 Million with Approximately 132,700 TRx SAN DIEGO , Jan.


Friday January 10, 2020

Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

Neurocrine Biosciences Owns Option to Exclusively License ACT-709478, a Clinical Stage Selective T-type Calcium Channel Blocker for the Treatment of Epilepsy Idorsia to Receive $45 Million Upfront Upon Exercise of the Option and up to $365 Million in Potential Development and Regulatory Milestone

Events